58 related articles for article (PubMed ID: 15876410)
21. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
[TBL] [Abstract][Full Text] [Related]
22. The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors.
Wu CJ; O'Rourke DM; Feng GS; Johnson GR; Wang Q; Greene MI
Oncogene; 2001 Sep; 20(42):6018-25. PubMed ID: 11593409
[TBL] [Abstract][Full Text] [Related]
23. Retinoic acid-induced growth arrest of MCF-7 cells involves the selective regulation of the IRS-1/PI 3-kinase/AKT pathway.
del Rincón SV; Rousseau C; Samanta R; Miller WH
Oncogene; 2003 May; 22(22):3353-60. PubMed ID: 12776186
[TBL] [Abstract][Full Text] [Related]
24. Effect of selective estrogen receptor modulator/raloxifene analogue on proliferation and collagen metabolism of tendon fibroblast.
Irie T; Takahata M; Majima T; Abe Y; Komatsu M; Iwasaki N; Minami A
Connect Tissue Res; 2010 Jun; 51(3):179-87. PubMed ID: 20073985
[TBL] [Abstract][Full Text] [Related]
25. Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells.
Bompard G; Puech C; Prébois C; Vignon F; Freiss G
J Biol Chem; 2002 Dec; 277(49):47861-9. PubMed ID: 12354757
[TBL] [Abstract][Full Text] [Related]
26. Antiestrogens increase protein tyrosine phosphatase activity in human breast cancer cells.
Freiss G; Vignon F
Mol Endocrinol; 1994 Oct; 8(10):1389-96. PubMed ID: 7854356
[TBL] [Abstract][Full Text] [Related]
27. Co-administration of finasteride and the pure anti-oestrogen ICI 182,780 act synergistically in modulating the IGF system in rat prostate.
Huynh H; Alpert L; Alaoui-Jamali MA; Ng CY; Chan TW
J Endocrinol; 2001 Oct; 171(1):109-18. PubMed ID: 11572795
[TBL] [Abstract][Full Text] [Related]
28. 17beta-estradiol, but not raloxifene, decreases thrombomodulin in the antithrombotic protein C pathway.
Richardson MA; Berg DT; Calnek DS; Ciaccia AV; Joyce DE; Grinnell BW
Endocrinology; 2000 Oct; 141(10):3908-11. PubMed ID: 11014248
[TBL] [Abstract][Full Text] [Related]
29. Selective estrogen receptor modulators suppress mesangial cell collagen synthesis.
Neugarten J; Acharya A; Lei J; Silbiger S
Am J Physiol Renal Physiol; 2000 Aug; 279(2):F309-18. PubMed ID: 10919851
[TBL] [Abstract][Full Text] [Related]
30. Mechanisms of 4-hydroxytamoxifen anti-growth factor activity in breast cancer cells: alterations of growth factor receptor binding sites and tyrosine kinase activity.
Freiss G; Rochefort H; Vignon F
Biochem Biophys Res Commun; 1990 Dec; 173(3):919-26. PubMed ID: 2268352
[TBL] [Abstract][Full Text] [Related]
31. Combinatorial PX-866 and Raloxifene Decrease Rb Phosphorylation, Cyclin E2 Transcription, and Proliferation of MCF-7 Breast Cancer Cells.
Peek GW; Tollefsbol TO
J Cell Biochem; 2016 Jul; 117(7):1688-96. PubMed ID: 26660119
[TBL] [Abstract][Full Text] [Related]
32. Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice.
Erlandsson MC; Jonsson CA; Lindberg MK; Ohlsson C; Carlsten H
J Endocrinol; 2002 Nov; 175(2):319-27. PubMed ID: 12429030
[TBL] [Abstract][Full Text] [Related]
33. A novel nongenomic action of estrogens: the regulation of exocytotic kinetics.
Machado JD; Alonso C; Morales A; Borges R
Ann N Y Acad Sci; 2002 Oct; 971():284-6. PubMed ID: 12438136
[No Abstract] [Full Text] [Related]
34. PTPL1: a large phosphatase with a split personality.
Abaan OD; Toretsky JA
Cancer Metastasis Rev; 2008 Jun; 27(2):205-14. PubMed ID: 18265946
[TBL] [Abstract][Full Text] [Related]
35. Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies.
Ozyurt R; Ozpolat B
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358625
[TBL] [Abstract][Full Text] [Related]
36. Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.
Baumann KH; Klusmeier E; Eggemann I; Reinartz S; Almeroth A; Kalder M; Wagner U
Breast Cancer (Auckl); 2009 Apr; 3():23-34. PubMed ID: 21556247
[TBL] [Abstract][Full Text] [Related]
37. PTPN13/PTPL1: an important regulator of tumor aggressiveness.
Freiss G; Chalbos D
Anticancer Agents Med Chem; 2011 Jan; 11(1):78-88. PubMed ID: 21235435
[TBL] [Abstract][Full Text] [Related]
38. Expression of the putative tumor suppressor gene PTPN13/PTPL1 is an independent prognostic marker for overall survival in breast cancer.
Révillion F; Puech C; Rabenoelina F; Chalbos D; Peyrat JP; Freiss G
Int J Cancer; 2009 Feb; 124(3):638-43. PubMed ID: 19004008
[TBL] [Abstract][Full Text] [Related]
39. Anti-growth factor activities of benzothiophenes in human breast cancer cells.
Freiss G; Galtier F; Puech C; Aknin C; Maudelonde T; Chalbos D; Vignon F
J Steroid Biochem Mol Biol; 2005 Apr; 94(5):451-60. PubMed ID: 15876410
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
